| Signalling component | Gene name | Splicing isoform activity | Type of cancer | Reference number |
| RTK | EGFR | Constitutively active receptor/soluble decoy isoform, enhanced signalling, survival, and tumorigenicity. | Glioblastoma, lung | [28, 47–49, 51, 56–58] | RTK | RON | Constitutively active receptor, enhanced signalling, invasion, and motility. | Glioblastoma, colon, breast, and gastric | [34, 35] | RTK | MET | Constitutively active receptor/soluble decoy isoform, enhanced/reduced signalling, invasion, and motility. | Ovarian, lung, and HCC | [38, 39] | RTK | FGFR | Induction of EMT, invasion, and motility. | Prostate, pancreatic, and breast | [28, 29, 36, 61] | RTK | INSR | Differential ligand binding (IGF-II) and oncogenic activity. | HCC, thyroid, and ovarian | [31, 37] | RTK | VEGFR | Soluble decoy isoform, enhanced/reduced angiogenesis, and survival. | Lung, breast | [28, 32] |
| Cytosolic kinase | Fyn | Enhanced/reduced kinase activity, survival of epithelial cells. | Unknown | [43] | Cytosolic kinase | mTOR | Constitutively active kinase, oncogenic activity. | HCC | [75] | Cytosolic kinase | S6K1 | Tumor suppressor/oncogenic isoforms, activates/inhibits mTORC1. | Breast, lung | [14, 78] | Cytosolic kinase | A-Raf | Enhanced/reduced binding to Ras and activation of the MAPK pathway. | HCC, head, and neck | [45, 46] | Cytosolic kinase | B-Raf | Enhanced/reduced kinase activity, activation of the MAPK pathway, and resistance to BRAF kinase inhibitors. | Colon, melanoma | [20, 21, 40] | Cytosolic kinase | MEK1 | Alternative pathway with a different substrate. | Unknown | [66, 67] | Cytosolic kinase | ERK1 | Alternative pathway with different substrates. | Unknown | [66, 67] | Cytosolic kinase | MKNK2 | Oncogenic isoform that enhances eIF4E phosphorylation and a tumor-suppressive isoform. | Lung, breast, colon, and pancreas | [14, 68] |
| Phospholipid phosphatase | PTEN | Active/inactive tumor suppressor. | Unknown | [71] | Phospholipid kinase | PI3K | Constitutively active kinase, enhanced downstream signalling. | Unknown | [69, 70] |
| Small GTPase | Ras | Enhanced/reduced binding to Raf and Rin and activation of the MAPK pathway. | Unknown | [32, 44] | GTPase activator (GAP) | TSC2 | Inactivation of a tumor suppressor. | Tuberous sclerosis | [72–74] |
|
|